POLG and Hepatic failure: Since then, several studies have demonstrated that patients with homozygous or compound heterozygous pathogenic variants on POLG1 (e.g., p.W748S and p.A467T) are at greater risk of liver failure induced by sodium valproate (VPA) [9, 10].